Jacob Kechter

Jacob Kechter

Auto-generated profile, based on publicly available information

Jacob Kechter

Department of Dermatology, Mayo Clinic, Scottsdale, Arizona, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
AHAngelina S. Hwang
Angelina S. Hwang
JKJacob A. Kechter
Jacob A. Kechter
XLXing Li
Xing Li
AHAlysia Hughes
Alysia Hughes
KSKevin J. Severson
Kevin J. Severson
AMAaron Mangold
Aaron Mangold


27 June 2024 in JID Innovations
Verified
Journal Article
Open access
AHAlysia N. Hughes
Alysia N. Hughes
XLXing Li
Xing Li
JLJulia S. Lehman
Julia S. Lehman
SNSteven A. Nelson
Steven A. Nelson
DDDavid DiCaudo
David DiCaudo
ASAleksandar Sekulic
Aleksandar Sekulic
Drug repurposing is an attractive strategy for therapy development, particularly in rare diseases where traditional drug development approaches may be challenging owing to high cost and small numbers of patients. In this study, we used a drug identification and repurposing pipeline to identify candidate targetable drivers of disease and corresponding therapies through application of causal reasoning using a combination of open-access resources and transcriptomics data. We optimized our approach on psoriasis as a disease model, demonstrating the ability to identify known and, to date, unrecognized molecular drivers of psoriasis and link them to current and emerging therapies. Application of our approach to a cohort of tissue samples of necrobiosis lipoidica (an unrelated; rare; and, to date, molecularly poorly characterized cutaneous inflammatory disorder) identified a unique set of upstream regulators, particularly highlighting the role of IFNG and the Jak–signal transducer and activator of transcription pathway as a likely driver of disease pathogenesis and linked it to Jak inhibitors as potential therapy. Analysis of an independent cohort of necrobiosis lipoidica samples validated these findings, with the overall agreement of drug-matched upstream regulators above 96%. These data highlight the utility of our approach in rare diseases and offer an opportunity for drug discovery in other rare diseases in dermatology and beyond.

11 January 2024 in medRxiv
Verified
Preprint
Open access
PDF file
AHAngelina Hwang
Angelina Hwang
JKJacob Kechter
Jacob Kechter
TDTran Do
Tran Do
AHAlysia Hughes
Alysia Hughes
NZNan Zhang
Nan Zhang
AMAaron R Mangold
Aaron R Mangold
Background: Cutaneous lichen planus (LP) is a recalcitrant, difficult-to-treat, inflammatory skin disease characterized by pruritic, flat-topped, violaceous papules on the skin. Baricitinib is an oral Janus kinase (JAK) 1/2 inhibitor that interrupts the signaling pathway of interferon (IFN)-γ, a cytokine implicated in the pathogenesis of LP. Methods: In this phase II trial, twelve patients with cutaneous LP received baricitinib 2 mg daily for 16 weeks, accompanied by in-depth spatial, single-cell, and bulk transcriptomic profiling of pre-and post-treatment samples. Results: An early and sustained clinical response was seen with 83.3% of patients responsive at week 16. Our molecular data identified a unique, oligoclonal IFN-γ, CD8+, CXCL13+ cytotoxic T-cell population in LP skin and demonstrate a rapid decrease in interferon signature within 2 weeks of treatment, most prominent in the basal layer of the epidermis. Conclusion: This study demonstrates the efficacy and molecular mechanisms of JAK inhibition in LP. Trial Registration Number : NCT05188521

14 February 2025 in Archives of Dermatological Research
Verified
Journal Article
Closed access
PDF file
NZNan Zhang
Nan Zhang
ASAlyssa Stockard
Alyssa Stockard
ZLZachary Leibovit-Reiben
Zachary Leibovit-Reiben
AHAngelina S. Hwang
Angelina S. Hwang
JKJacob A. Kechter
Jacob A. Kechter
AMAaron R. Mangold
Aaron R. Mangold

6 February 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SNShams Nassir
Shams Nassir
MYMiranda Yousif
Miranda Yousif
XLXing Li
Xing Li
KSKevin Severson
Kevin Severson
AHAlysia Hughes
Alysia Hughes
AMAaron R Mangold
Aaron R Mangold
Cutaneous squamous cell carcinoma (cSCC) is one of the most common cancers in humans and kills as many people annually as melanoma. The mutational and transcriptional landscape of cSCC has identified driver mutations associated with disease progression as well as key pathway activation in the progression of pre-cancerous lesions. The understanding of the transcriptional changes with respect to high-risk clinical/histopathological features and outcome is poor. Here, we examine stage-matched, outcome-differentiated cSCC and associated clinicopathologic risk factors using whole exome and transcriptome sequencing on matched samples. Exome analysis identified key driver mutations including TP53 , CDKN2A , NOTCH1 , SHC4 , MIIP , CNOT1 , C17orf66 , LPHN22 , and TTC16 and pathway enrichment of driver mutations in replicative senescence, cellular response to UV, cell-cell adhesion, and cell cycle. Transcriptomic analysis identified pathway enrichment of immune signaling/inflammation, cell-cycle pathways, extracellular matrix function, and chromatin function. Our integrative analysis identified 183 critical genes in carcinogenesis and were used to develop a gene expression panel (GEP) model for cSCC. Three outcome-related gene clusters included those involved in keratinization, cell division, and metabolism. We found 16 genes were predictive of metastasis (Risk score ≥ 9 Met & Risk score < 9 NoMet). The Risk score has an AUC of 97.1% (95% CI: 93.5% - 100%), sensitivity 95.5%, specificity 85.7%, and overall accuracy of 90%. Eleven genes were chosen to generate the risk score for Overall Survival (OS). The Harrell’s C-statistic to predict OS is 80.8%. With each risk score increase, the risk of death increases by 2.47 (HR: 2.47, 95% CI: 1.64-3.74; p<0.001) after adjusting for age, immunosuppressant use, and metastasis status.